Levofloxacin/amoxicillin-based schemes vs quadruple therapy for Helicobacter pylori eradication in second-line

Table 2 Levofloxacin-based second-line therapies vs quadruple bismuth-based regimens for Helicobacter pylori treatment

Ref.	Ethnicity	Scheme	Success					Side effects			Discontinuing therapy because of side effects
			Yes	Total	Completing	ITT %	PP %	Yes	Total	%	Yes	Total	%
Nista et al[21]	Caucasian	LAR (10 d; L: 500 mg OD)	66	70	70	94.3	94.3	7	70	10.0	0	70	0.0
		Q07	44	70	64	62.9	68.8	15	70	21.4	5	70	7
Perri et al[29]	Caucasian	LAP (7 d; L: 500 mg OD)	37	58	56	63.8	66.1	3	58	5.2	1	58	1.7
		Q07	46	55	51	83.6	90.2	17	55	30.9	3	55	5.5
Orsi et al1[38]	Caucasian	LAR (12 d; L: 500 mg OD)	43	50	47	86.0	89	4	47	8.5	NA	NA	NA
		Q07	44	50	44	88.0	91	11	44	25	NA	NA	NA
Bilardi et al[39]	Caucasian	LAP (10 d; L: 250 mg BD)	16	23	NA	69.6	NA	-	-	-	1	44
		Q07	6	17	NA	35.3	NA	-	-	-	1	46
Nista et al1[35]	Caucasian	LAE (10 d; L: 500 mg OD)	26	30	30	86.7	86.7	-	-	-
		Q07	25	35	31	71.4	80.6	-	-	-
Nista et al1[36]	Caucasian	LAR (10 d; L: 500 mg OD)	42	46	46	91.3	91.3	-	-	-
		LAR (7 d; L: 500 mg OD)	37	50	50	74.0	74.0	-	-	-
		Q07	34	50	46	68	73.9	-	-	-
Gisbert et al[28]	Caucasian	LAO (7 or 10 d; L: 500 mg BD)	83	112	NA	74	NA	39	112	34.8	NA	NA	NA
		Q07	21	38	NA	55	NA	6	38	15.8	NA	NA	NA
Wong et al1[44]	Asian	LALa (7 d; L: 500 mg BD)	21	33	NA	63.6	NA	-	-	-
		Q07	22	30	NA	73.3	NA	-	-	-
Lee et al[80]	Asian	LAR (10 d; L: 200 mg BD)	5	9	8	55.6	62.5	-	-	-
		Q07	4	14	10	28.6	40.0	-	-	-
Wong et al[19]	Asian	LALa (7 d; L: 500 mg BD)	19	31	NA	61.3	NA	18	542	33.3	NA	NA	NA
		Q07	26	30	NA	86.7	NA	21	522	40.4	NA	NA	NA
Zhang et al[43]	Asian	LAE (7 d; L: 500 mg OD)	42	49	NA	85.7	NA
		Q07	30	44	NA	68.2	NA
Zhang et al[37]	Asian	LAE (7 d; L: 500 mg OD)	42	48	46	87.5	91.3	7	48
		Q07	33	47	34	70.2	97.0	15	47
Jung et al[42]	Asian	LAP (7 d; L: 300 mg BD)	16	31	30	51.6	53.3	3	30	10.0	0	31	0.0
		Q07	22	45	35	48.9	62.9	11	35	31.4	1	45	2.2
Kuo et al[41]	Asian	LAE (7 d; L: 500 mg OD)	58	83	77	69.9	75.3	10	80	12.5	1	83
		Q07	53	83	63	63.9	84.1	25	71	35.2	5	83

¹Data arisen from abstract publication;

²side effects calculated on the entire study population (not stratified for number of failed previous therapy). L: Levofloxacin; OD: Once daily; BD: Twice daily; LA/La: Levofloxacin/Lansoprazole; ITT: Intention-to-treat eradication rates; PP: Per-protocol; NA: Not available; LAR: Levofloxacin/amoxicillin/rabeprazole; LAO: Levofloxacin/amoxicillin/omeprazole; LAE: Levofloxacin/amoxicillin/esomeprazole; LAP: Levofloxacin/amoxicillin/pantoprazole.